ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 18

Identification of 14-3-3å As a New Subchondral Bone Mediator Involved in Cartilage Degradation During Osteoarthritis

Sabrina Priam Jr.1, Carole Bougault1, Xavier Houard2, Marjolaine Gosset3, Colette Salvat4, Francis Berenbaum5 and Claire Jacques1, 1Ur-4, Pierre et Marie Curie University Paris VI, Paris, France, 2Sorbonne Universités, UPMC Univ Paris 06, UMRS 938 and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Paris, France, 3EA 2496, Paris Descartes University, Montrouge, France, 4UR4, University Pierre and Marie Curie, Paris, France, 5Rheumatology, AP-HP, St Antoine Hospital, Paris, France

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: chondrocytes, matrix metalloproteinase (MMP), Osteoarthritis, osteoblasts and proteomics

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Biology and Pathology of Bone and Joint

Session Type: Abstract Submissions (ACR)

Background/Purpose: OA is a complex disease not limited to cartilage degeneration. Indeed, several experiments suggest that subchondral bone remodeling could initiate and/or contribute to cartilage loss in OA through a bone/cartilage interplay. We aimed to identify soluble mediators released by loaded osteoblasts/osteocytes that could induce the release of pro-catabolic factors by chondrocytes by using a novel and unique bone/cartilage communication model.

Methods: Thanks to a three dimensional (3D) culture model, murine osteoblasts were submitted to compression in Biopress Flexercell plates (1.7 MPa, 1Htz during 24h). Then, conditioned media from compressed (CM) or uncompressed (UCM) osteoblasts/osteocytes were used to stimulate mouse articular chondrocytes. Chondrocyte expression of matrix metalloproteinase 3 (MMP-3) and MMP-13, tissue inhibitors of metalloproteinases (TIMPs), and cartilage extracellular matrix components type II collagen and aggrecan were assessed by RT-PCR, western blot analysis and ELISA. Then, soluble mediators released by compressed osteoblasts/osteocytes were identified by iTRAQ®, a differential secretomic analysis approach.

Results: Media from compressed osteoblast (CM) strongly induced MMP-3 and -13 chondrocyte mRNA expression (Table). Consistently, CM also significantly stimulated the releases of MMP-3 and -13 by chondrocytes (respectively 10.6±0.75 fold, p<0.001, and 6.5±2.1 fold, p<0.01 compared to control). In addition, CM enhances TIMP-1 expression whereas it strongly inhibited TIMP-2 and -3 expressions (Table). CM also affected cartilage matrix proteins expressions by downregulating aggrecan and type II collagen mRNA levels (Table). Effects of CM on cytosolic type II collagen protein amounts were confirmed by western blot (a decrease of 31±9%, p<0.01). In order to identify osteoblast soluble mediators responsible for this chondrocyte phenotype, osteoblast conditioned media were analyzed by iTRAQ®. This sophisticated proteomic technique allowed identification of 105 proteins secreted by osteoblasts among which only 10% were upregulated in response to compression. Among them, 14-3-3ε dose-dependently induced the release of pro-catabolic factors by chondrocytes, mimicking the effects of CM osteoblasts/osteocytes media. Furthermore, 14-3-3ε was strongly released by human OA subchondral bone and stimulated MMP-3 expression in human OA chondrocytes.

Table:Effects of media from uncompressed or compressed osteoblasts on MMPs, TIMPs and matrix proteins chondrocytes mRNA expression. 

 

 

MMP-3

MMP-13

TIMP-1

TIMP-2

TIMP-3

Collagen II

Aggrecan

UCM

5,9±3

3,4±0,4

1,5±0,4

0,7±0,2

0,6±0,1

0,7±0,3

0,7±0,3

ns

ns

ns

p<0,01

p<0,001

ns

ns

CM

50,9±14,5

18,3±10,9

5,2±1,6

0,5±0,1

0,1±0,05

0,4±0,1

0,2±0,1

p<0,001

p<0,01

p<0,001

p<0,001

p<0,001

p<0,01

p<0,001

       Results are expressed in fold compared to control (non-stimulated chondrocytes).

Conclusion: Therefore, we identify 14-3-3ε as a novel soluble mediator critical in the communication between subchondral bone and cartilage in OA leading to MMP expression by chondrocytes. We speculate that 14-3-3ε is a potential target for a future disease-modifying OA drug.


Disclosure:

S. Priam Jr.,
None;

C. Bougault,
None;

X. Houard,
None;

M. Gosset,
None;

C. Salvat,
None;

F. Berenbaum,
None;

C. Jacques,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-14-3-3a-as-a-new-subchondral-bone-mediator-involved-in-cartilage-degradation-during-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology